Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 2
2020 2
2021 6
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Pazopanib-Associated Transient Ischemic Attack.
Revuelta-Herrero JL, Escudero-Vilaplana V, Álvarez-Álvarez R, Sanjurjo-Sáez M. Revuelta-Herrero JL, et al. Am J Ther. 2018 May/Jun;25(3):e393-e394. doi: 10.1097/MJT.0000000000000710. Am J Ther. 2018. PMID: 29424756 No abstract available.
Patient-reported outcome measures in severe asthma: an expert consensus.
Martínez-Moragón E, Antepara Ercoreca I, Muñoz García M; PROs-SA group of experts; Casas Maldonado F, Calvín Lamas M, Chiner Vives E, Crespo Diz C, Díaz-Pérez D, Eguiluz Gracia I, García Gil S, González-Pérez R, Habernau Mena A, Hermida Valverde T, Jornet Montaña S, López-Carrasco V, Martínez López I, Merino-Bohórquez V, Moreno-Ancillo Á, Mínguez Cabeza AC, Monte-Boquet E, Revuelta-Herrero JL, Sánchez-Cuellar S. Martínez-Moragón E, et al. Among authors: revuelta herrero jl. J Asthma. 2024 Jun;61(6):619-631. doi: 10.1080/02770903.2023.2297372. Epub 2023 Dec 26. J Asthma. 2024. PMID: 38146964
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, Giménez-Manzorro Á, Ribed A, Marzal-Alfaro B, Revuelta-Herrero JL, Gonzalez-Haba E, Herranz A, Sanjurjo M. Villanueva-Bueno C, et al. Among authors: revuelta herrero jl. Expert Opin Drug Saf. 2022 Jan;21(1):107-119. doi: 10.1080/14740338.2021.1965990. Epub 2021 Aug 12. Expert Opin Drug Saf. 2022. PMID: 34357828 Review.
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.
García-Sánchez S, Collado-Borrell R, González-Haba E, Revuelta-Herrero JL, Escudero-Vilaplana V, Marzal-Alfaro MB, Sánchez-Fresneda MN, Mur-Mur A, Herranz A, Martín M, Sanjurjo M. García-Sánchez S, et al. Among authors: revuelta herrero jl. Front Oncol. 2022 Jun 8;12:889575. doi: 10.3389/fonc.2022.889575. eCollection 2022. Front Oncol. 2022. PMID: 35756684 Free PMC article.
Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease.
Melgarejo-Ortuño A, Escudero-Vilaplana V, Revuelta-Herrero JL, Bailen R, Collado-Borrell R, Gomez-Centurión I, Oarbeascoa G, Kwon M, Herranz-Alonso A, Diez-Martin JL, Sanjurjo-Saez M. Melgarejo-Ortuño A, et al. Among authors: revuelta herrero jl. J Oncol Pharm Pract. 2021 Apr;27(3):751-755. doi: 10.1177/1078155220948934. Epub 2020 Aug 12. J Oncol Pharm Pract. 2021. PMID: 32787560
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.
Vicente-Valor J, Escudero-Vilaplana V, Collado-Borrell R, López-López C, Villanueva-Bueno C, Revuelta-Herrero JL, Ruiz-Briones P, Somoza-Fernández B, Herranz A, Sanjurjo M. Vicente-Valor J, et al. Among authors: revuelta herrero jl. J Oncol Pharm Pract. 2022 Jul;28(5):1259-1263. doi: 10.1177/10781552221074621. Epub 2022 Jan 17. J Oncol Pharm Pract. 2022. PMID: 35037798
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.
Escudero-Vilaplana V, Collado-Borrell R, Gómez Martínez-Sagrera P, Villanueva-Bueno C, Revuelta-Herrero JL, Gonzalez-Haba E, Hoyo-Muñoz Á, Jerez Gilarranz Y, Marzal-Alfaro B, Herranz A, Martin M, Sanjurjo M. Escudero-Vilaplana V, et al. Among authors: revuelta herrero jl. J Cancer Res Clin Oncol. 2023 Jul;149(7):2855-2882. doi: 10.1007/s00432-022-04172-1. Epub 2022 Jul 6. J Cancer Res Clin Oncol. 2023. PMID: 35790560
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.
Villanueva-Bueno C, Collado-Borrell R, Escudero-Vilaplana V, Revuelta-Herrero JL, Marzal-Alfaro MB, González-Haba E, Arranz-Arija JÁ, Osorio S, Herranz-Alonso A, Sanjurjo-Saez M. Villanueva-Bueno C, et al. Among authors: revuelta herrero jl. Front Public Health. 2022 Nov 4;10:978783. doi: 10.3389/fpubh.2022.978783. eCollection 2022. Front Public Health. 2022. PMID: 36407983 Free PMC article.
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V, Collado-Borrell R, Del Monte-Millán M, Hoyo-Muñoz A, Gómez Martínez-Sagrera P, Revuelta-Herrero JL, Marzal-Alfaro B, Gonzalez-Haba E, López-Tarruella Cobo S, Jerez Gilarranz Y, Herranz A, Sanjurjo M, Martin M. Escudero-Vilaplana V, et al. Among authors: revuelta herrero jl. Support Care Cancer. 2021 Aug;29(8):4673-4681. doi: 10.1007/s00520-021-06016-z. Epub 2021 Jan 28. Support Care Cancer. 2021. PMID: 33506273
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.
Villalvazo P, Marzal-Alfaro B, García-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, García-González X, Calvo A, Yakoubi M, Salvador-Martín S, López-López F, Aguilar I, Sanjurjo-Sáez M, Martín M, López-Fernández LA. Villalvazo P, et al. Among authors: revuelta herrero jl. J Pers Med. 2021 Aug 13;11(8):792. doi: 10.3390/jpm11080792. J Pers Med. 2021. PMID: 34442436 Free PMC article.
20 results